Clinical Experience With the Long-term Use of 1% Apraclonidine
Authors:
- Molly MannschreckMMMolly Mannschreck
- Shan LinSLShan Lin
- Ivan HwangIHIvan Hwang
- Jorge AlvaradoJAJorge Alvarado
- 1 March 1995
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 113 (3) , 293-296
Abstract
Objective: To identify the incidence and characteristics of allergic reactions associated with the long-term use of 1% apraclonidine hydrochloride. Methods: We undertook a retrospective analysis of 64 patients receiving long-term 1% apraclonidine therapy at the University of California—San Francisco Glaucoma Service. Patients were excluded if the duration of treatment was less than 2 weeks. Demographic data, initial intraocular pressure response, and incidence and characteristics of allergic reactions were obtained through chart review. Student'sttest and χ2analysis were used to analyze the demographic data, and Kaplan-Meier survival analysis was used to estimate the long-term incidence of local reactions. Results: Sixty-four patients met the criteria for the study. Of these, 31 (48%) developed an allergic reaction (responders) that led to discontinuation of treatment with the medication, with a mean latency of 4.7 months. Mean follow-up was 13.3 months. Patients free of local reactions (nonresponders) for at least 10 months were able to successfully continue apraclonidine use. Responders tended to be older and female. Conclusions: Our data are specific for the 1% preparation; however, physicians prescribing apraclonidine on a long-term basis should be aware of possible allergic reactions. A substantial percentage of patients developed this side effect, but most tolerated the medication for up to 4 months, and those without a local reaction after 10 months appeared to be able to continue apraclonidine use indefinitely. This allergic reaction is likely related to the adrenergic agent itself, and not to preservatives.Keywords
This publication has 16 references indexed in Scilit:
- Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteersInternational Ophthalmology, 1992
- Apraclonidine and early postoperative intraocular hypertension after cataract extractionActa Ophthalmologica, 1992
- Control of Intraocular Pressure With Apraclonidine Hydrochloride After Cataract ExtractionAmerican Journal of Ophthalmology, 1991
- Follicular Conjunctivitis Associated With ApraclonidineAmerican Journal of Ophthalmology, 1991
- Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of ApraclonidineArchives of Ophthalmology (1950), 1990
- Aqueous Flow is Reduced by the Alpha-adrenergic Agonist, Apraclonidine Hydrochloride (ALO 2145)Ophthalmology, 1988
- Short-term Effects of Unilateral 1% Apraclonidine TherapyArchives of Ophthalmology (1950), 1988
- Effects of Topical ALO 2145 (p-Aminoclonidine Hydrochloride) on the Acute Intraocular Pressure Rise After Argon Laser IridotomyArchives of Ophthalmology (1950), 1987
- The Safety and Efficacy of Topical 1% ALO 2145 (p-Aminoclonidine Hydrochloride) in Normal VolunteersArchives of Ophthalmology (1950), 1987
- External Ocular Toxicity of Dipivalyl EpinephrineAmerican Journal of Ophthalmology, 1979